Summary: A novel vaccine strategy can direct the immune system to precisely attack gliomas, one of the most lethal types of brain tumor. This breakthrough demonstrates that immune cells can be trained to recognize proteins bearing cancer-driving mutations, opening a new avenue for targeted cancer immunotherapy.
Clinical trials have confirmed that vaccines focused on the IDH1 mutation—found in many gliomas—are safe and can provoke effective, mutation-specific immune responses. For this work, Michael Platten received the “Breakthrough of the Year 2024” recognition, underscoring the potential impact of this approach on future cancer treatment.
Key facts
- Vaccines were developed to focus immune responses on the IDH1 mutation, a key driver in many gliomas.
- Early clinical trials show these vaccines are safe and able to elicit targeted immune activity against tumor cells.
- This precision immunotherapy concept could be extended to other cancers that share clonal, mutation-derived targets.
Source: DKFZ
Michael Platten’s research aims to improve outcomes for patients with aggressive brain tumors, particularly gliomas.
Platten and his team have shown that the immune system can be mobilized by novel vaccines to recognize and attack cancer cells in the brain. These vaccines teach the body’s defenses to distinguish between normal proteins and those altered by tumor-driving mutations, enabling a highly specific immune response against malignant cells.
On November 9, 2024, Platten will be honored with the “Breakthrough of the Year 2024” award from the Falling Walls Foundation in Berlin for this pioneering work.
Platten leads the Clinical Cooperation Unit for Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center (DKFZ) and serves as director of the Department of Neurology at the University Medical Center Mannheim (UMM). Since October he has also taken on the role of president of the European Association of Neuro-Oncology (EANO).
His close work with patients informs his research priorities. “My inspiration comes primarily from the patients who struggle with this devastating disease every day,” Platten says. He emphasizes that scientific advances should translate into tangible improvements in patients’ lives.
Breaking the barrier for brain tumor vaccines
Clinical studies have validated the core idea: a vaccine can activate a patient’s immune system to recognize and attack tumor cells in the brain. These trials have shown the vaccines to be both safe and effective in generating targeted immune responses. For Platten and his team, demonstrating that a vaccine can trigger a focused immune reaction inside a brain tumor was a pivotal breakthrough.
Precision tumor therapy
The defining strength of this approach is its precision. Once trained by the vaccine, immune cells can detect even subtle differences between normal proteins and proteins changed by cancer-driving mutations. Platten’s group identified the IDH1 mutation as a critical and frequent alteration in gliomas—present in nearly 70 percent of low-grade gliomas—making it an ideal target for mutation-focused immunotherapy.
By directing the immune system specifically against the IDH1 mutation, the vaccine can mount a broad attack against all tumor cells that carry that mutation, even when those tumor cells are genetically diverse. This targeted elimination reduces collateral damage to healthy tissue and improves the potential for durable disease control.
Potential applications beyond brain tumors
Using advanced bioinformatics and molecular biology, Platten’s team has developed cellular immunotherapies that could be adapted to other cancers. The central concept is to identify mutations that are present in all tumor cells within a patient—so-called clonal driver mutations—then train the immune system to recognize them.
When a tumor’s driving mutation is shared across its cells, a vaccine targeting that mutation can generate an immune response that reaches every malignant cell, regardless of additional genetic differences. This strategy increases the likelihood of comprehensive tumor control and may broaden the applicability of such vaccines across cancer types.
Platten also aims to inspire new researchers: “Be brave, ask questions, work in teams and share your knowledge. And if necessary, don’t be afraid to break into completely new fields of research,” he advises young scientists.
Falling Walls Science Summit 2024
The Falling Walls Science Breakthrough of the Year award is presented annually to recognize outstanding scientific achievements across categories of the Falling Walls Global Call. Winners present their work at the Falling Walls Science Summit in Berlin. Michael Platten was selected as one of ten winners in the Life Sciences category and named Breakthrough of the Year 2024 in Life Sciences.
About this brain cancer research news
Author: Sibylle Kohlstädt
Source: DKFZ
Contact: Sibylle Kohlstädt – DKFZ
Image: The image is credited to Neuroscience News
Original research presentation: Michael Platten’s lecture will be presented at the Falling Walls Science Summit on November 9, 2024, and can be followed online via the event program.